重组干扰素α-1b治疗慢性丙型肝炎的疗效研究

Analysis of the efficacy of recombinant interferon α-1b in treatment of chronic hepatitis C

目的 :探讨重组干扰素α 1b(赛若金 )治疗慢性丙型肝炎的疗效及不良反应。方法 :选择慢性丙型肝炎患者 65例 ,随机分成治疗组 35例 ,给予赛若金治疗 ,第 1～ 4周 30 μg·d-1,im ;第 5～ 16周为隔日 30 μg ,im。对照组 30例 ,按常规给予降酶、退黄及护肝药物。结果 :2组ALT及SBIL均有显著下降 ,但治疗组疗效显著高于对照组 (P <0 .0 5 )。治疗组抗丙型肝炎病毒转阴率为 37.1% ,显著高于对照组 (3.3% ) (P <0 .0 5 ) ,未见严重的药物不良反应。结论 :赛若金治疗慢性丙型肝炎 ,安全有效 。

Objective:To study the efficacy and side effects of recombinant interferon α 1b(Sinogen) in treatment of chronic hepatitis C.Methods:65 patients were randomly divided to receive 30μg·d -1 im Sinogen at weeks 1～4 and 30μg every 2 days im Sinogen at weeks 5～16( n =35),or receive placebo including drugs to reduce liver enzyme and jaundice and agent for liver protection( n =30).Results:ALT and SBIL were significantly decreased in both of the two groups,but the efficacy of the active arm was better than that of the control arm.The HCV eradication rate of the active arm was 37.1%, which was significantly higher than the corresponding figure(3.3%) of the control arm.Conclusion:Interferon α 1b is an effective agent for treatment of chronic hepatitis C. [